FindTrial
Sign In

To assess frequency of Diffuse Large B Cell Lymphoma genetic subtypes in India

The Molecular Landscape of Diffuse Large B Cell Lymphomas on the Indian Sub- continent.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/10/016107
Enrollment
350
Registered
2018-10-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Denovo DLBCL cases registered at Tata Memorial Center from 2007 to 2013 will be screened. Out of these 350 cases will be enrolled based on availability of FFPE Health Condition 2: D728- Other specified disorders of whiteblood cells

Interventions

None listed

Sponsors

Duke Cancer Institute for Genome Science and Policy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Age >15 years 2 Denovo DLBCL cases who were treated in department of Medical Oncology

Exclusion criteria

Exclusion criteria: 1.Non availability of formalin- fixed paraffin blocks 2.Non availability of Outcome Data

Design outcomes

Primary

MeasureTime frame
1. Evaluating the frequency of GCB and ABC DLBCL subtypes with gene expression 2. Comparison of frequency of DLBCL molecular subtypes (comparison of our data set with that of North America- Dr Daveâ??s lab data) 3. RNA sequencing to identify DLBCL subtypes and its correlation with GEP subtypes profiling Timepoint: 3 years—

Secondary

MeasureTime frame
Effect of ABC and GCB subtypes on overall survivalTimepoint: 36 months—

Countries

India

Contacts

Public ContactDr Manju Sengar

TATA MEMEORIAL CENTRE

manju.sengar@gmail.com02224177211

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026